news

News



    • 03/22/2017
      XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement from Existing Investors
      READ MORE >>
    • 03/07/2017
      XTL Biopharmaceuticals Announces $2.8 Million Private Placement from Existing Investors
      READ MORE >>
    • 03/01/2017
      XTL Biopharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
      READ MORE >>
    • 02/17/2017
      XTL Biopharmaceuticals Announces $2.5 Million Registered Direct Offering
      READ MORE >>
    • 02/13/2017
      XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of hCDR1 in Sjӧgren's Syndrome
      READ MORE >>
    • 01/25/2017
      XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program
      READ MORE >>
    • 01/05/2017
      XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potential in the Treatment of Sjogren's Syndrome
      READ MORE >>